Scholarlink

<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and neuronal dysfunction. Despite advancements in understanding AD pathology, including β-amyloid plaques and tau neurofibrillary tangles, effective disease-modifying treatments remain limited. Natural compounds are being explored for their therapeutic potential in AD. Asperuloside, a bioactive iridoid glycoside, has demonstrated multi-target activity, particularly through modulation of NF-κB, Nrf2/ARE, and Wnt/β-catenin pathways, implicated in neuronal survival and synaptic plasticity. These mechanisms are relevant to AD pathology involving neuroinflammation, oxidative stress, and synaptic dysfunction, although most evidence derives from peripheral or <i>in vitro</i> models. Emerging studies using AD-specific <i>in vivo</i> (e.g., <i>C. elegans</i>) and cellular models (e.g., Aβ-expressing SH-SY5Y cells) provide disease-relevant insights into ASP neuroprotective potential. This review focuses on disease-specific insights into Asperuloside therapeutic actions in AD, highlighting the need for further validation using transgenic mouse models and iPSC-derived neurons.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Asperuloside as a promising multi-target agent for Alzheimer’s disease: molecular mechanisms and therapeutic perspectives

  • 期刊论文

  • 发表日期：

    2025年7月28日

查看全文
  • Kanika Vashisht,
  • Himanshu Kumar,
  • Amardeep Ankalgi,
  • Mahendra Singh Ashawat,
  • Rimpi,
  • Shiv Kumar Kushawaha,
  • Ashish Baldi

摘要

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and neuronal dysfunction. Despite advancements in understanding AD pathology, including β-amyloid plaques and tau neurofibrillary tangles, effective disease-modifying treatments remain limited. Natural compounds are being explored for their therapeutic potential in AD. Asperuloside, a bioactive iridoid glycoside, has demonstrated multi-target activity, particularly through modulation of NF-κB, Nrf2/ARE, and Wnt/β-catenin pathways, implicated in neuronal survival and synaptic plasticity. These mechanisms are relevant to AD pathology involving neuroinflammation, oxidative stress, and synaptic dysfunction, although most evidence derives from peripheral or in vitro models. Emerging studies using AD-specific in vivo (e.g., C. elegans) and cellular models (e.g., Aβ-expressing SH-SY5Y cells) provide disease-relevant insights into ASP neuroprotective potential. This review focuses on disease-specific insights into Asperuloside therapeutic actions in AD, highlighting the need for further validation using transgenic mouse models and iPSC-derived neurons.